1. Home
  2. MEDP vs MDGL Comparison

MEDP vs MDGL Comparison

Compare MEDP & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medpace Holdings Inc.

MEDP

Medpace Holdings Inc.

HOLD

Current Price

$449.54

Market Cap

11.9B

Sector

Health Care

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$500.99

Market Cap

11.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEDP
MDGL
Founded
1992
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9B
11.5B
IPO Year
2016
2005

Fundamental Metrics

Financial Performance
Metric
MEDP
MDGL
Price
$449.54
$500.99
Analyst Decision
Hold
Strong Buy
Analyst Count
12
12
Target Price
$473.17
$674.45
AVG Volume (30 Days)
309.6K
264.8K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
20.98
41.32
EPS
4.28
N/A
Revenue
N/A
$180,133,000.00
Revenue This Year
$13.19
$58.39
Revenue Next Year
$7.75
$48.55
P/E Ratio
$104.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$291.28
$268.69
52 Week High
$628.92
$615.00

Technical Indicators

Market Signals
Indicator
MEDP
MDGL
Relative Strength Index (RSI) 56.69 42.89
Support Level $447.80 $498.59
Resistance Level $477.04 $502.97
Average True Range (ATR) 14.05 19.95
MACD 5.18 -1.98
Stochastic Oscillator 90.75 15.53

Price Performance

Historical Comparison
MEDP
MDGL

About MEDP Medpace Holdings Inc.

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: